VTYX — Ventyx Biosciences Share News
0.000.00%
Last trade - 00:00Ventyx Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ventyx Biosciences Q2 Net Income USD -53.251 Million
Ventyx Biosciences Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Ventyx Biosciences Announces Initiation Of Dosing In A Phase 1 Trial Of Vtx3232, A Novel Cns-Penetrant Nlrp3 Inhibitor
U.S. STOCKS ON THE MOVE-Biogen, Phoenix Motor, Mastercard
U.S. STOCKS ON THE MOVE-Energy sector, Affirm, Stitch Fix
Ventyx rises on completion of enrollment in two mid-stage trials
Brief: Ventyx Biosciences Announces Completion Of Enrollment Of Phase 2 Trial Of VTX002 In Ulcerative Colitis
Ventyx Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ventyx Biosciences Reports First Quarter 2023 Financial Results
Brief: Ventyx Biosciences Q1 net loss USD 38.931 million
Ventyx Biosciences Inc expected to post a loss of 65 cents a share - Earnings Preview
Big pharma interest in immunology sector to grow in near to medium term - Jefferies
Ventyx Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ventyx Biosciences Reports Q4 EPS USD -0.62
Brief: Ventyx Biosciences Reports Fourth Quarter Results
Ventyx Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Ventyx Biosciences Provides Update On Silicon Valley Bank Financial Exposure
Brief: Third Point LLC Takes Stake In Microsoft, Dissolves in Take-Two and EQT Corp